Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fludarabine Phosphate in EGFR mutation Glioblastoma: NCT06186401 Clinical Landscape Report 2026
15 October 2026
NCT06186401 clinical landscape for EGFR mutation Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zalfermin in Metabolic Dysfunction Associated Steatohepatitis: NCT06188026 Clinical Landscape Report 2026
15 October 2026
NCT06188026 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
S-095035 in Glioblastoma, IDH-Wildtype: NCT06188702 Clinical Landscape Report 2026
15 October 2026
NCT06188702 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cerebroprotein Hydrolysate in Amyotrophic Lateral Sclerosis: ISRCTN38393880 Clinical Landscape Report 2026
15 October 2026
ISRCTN38393880 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Langqing A'ta Granules in Metabolic Dysfunction Associated Steatohepatitis: NCT06193629 Clinical Landscape Report 2026
15 October 2026
NCT06193629 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
NV-A01 in Glioblastoma: NCT06193538 Clinical Landscape Report 2026
15 October 2026
NCT06193538 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MB-108 in Gliosarcoma: NCT06193174 Clinical Landscape Report 2026
15 October 2026
NCT06193174 clinical landscape for Gliosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ertugliflozin pidolate in Diabetes Mellitus, Type 2: ACTRN12624000032550 Clinical Landscape Report 2026
15 October 2026
ACTRN12624000032550 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Nivolumab in Glioblastoma, IDH-Wildtype: ISRCTN30298528 Clinical Landscape Report 2026
15 October 2026
ISRCTN30298528 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dapagliflozin in Diabetes Mellitus, Type 2: ACTRN12624000039583 Clinical Landscape Report 2026
15 October 2026
ACTRN12624000039583 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
IMM-H014 in Metabolic Dysfunction Associated Steatohepatitis: NCT06216041 Clinical Landscape Report 2026
15 October 2026
NCT06216041 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
VRG-50635 in Amyotrophic Lateral Sclerosis: NCT06215755 Clinical Landscape Report 2026
15 October 2026
NCT06215755 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.